TY - JOUR
T1 - Vision-related quality of life in adults with severe peripheral vision loss
T2 - a qualitative interview study
AU - Lange, Ryan
AU - Kumagai, Abigail
AU - Weiss, Sara
AU - Zaffke, Katherine B.
AU - Day, Sherry
AU - Wicker, Donna
AU - Howson, Ashley
AU - Jayasundera, K. Thiran
AU - Smolinski, Lori
AU - Hedlich, Christina
AU - Lee, Paul P.
AU - Massof, Robert W.
AU - Stelmack, Joan A.
AU - Carlozzi, Noelle E.
AU - Ehrlich, Joshua R.
N1 - Funding Information:
National Institutes of Health to Joshua R. Ehrlich (K23EY027848). An unrestricted grant from Research to Prevent Blindness to the Department of Ophthalmology and Visual Sciences at the University of Michigan. The sponsor or funding organizations had no role in the design or conduct of this research.
Funding Information:
The authors would like to acknowledge Dr. Ecosse Lamoureux, Dr. Eva Fenwick, and the Singapore Eye Research Institute for providing the Impact of Vision Impairment Questionnaire for use in this study. Richard Stevens, J.D., the executive director of the Association for the Blind and Visually Impaired (ABVI), was instrumental in arranging for the organization?s participation in this study.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Background: Existing patient-reported outcome (PRO) measures may not be relevant to the full range of functional and vision-related quality of life (VR-QOL) concerns of individuals with vision impairment due to severe peripheral field loss (PFL). Measurement of VR-QOL in severe PFL is important in order to determine the effectiveness of vision rehabilitation interventions for this population. The purpose of this study was to characterize the impact of severe PFL due to retinitis pigmentosa (RP) and glaucoma on VR-QOL as the initial phase in the development of a novel PRO measure. Methods: Individuals with severe PFL due to RP or glaucoma were recruited from the Kellogg Eye Center and the Association for the Blind and Visually Impaired. Participants completed semi-structured qualitative interviews, the Impact of Vision Impairment (IVI) questionnaire and the RAND 36-Item Health Survey. Interviews were analyzed by two coders using thematic analysis. A matrix analysis was conducted to compare VR-QOL by cause of severe PFL. Sample size was determined by thematic saturation. Results: The study included 37 participants (19 RP, 18 glaucoma). Median best-corrected visual acuity for those with RP and glaucoma was 20/40 and 20/27.5, while Pelli-Robson contrast sensitivity was 1.2 log contrast sensitivity (logCS) and 1.1 logCS, respectively. Median domain scores on the IVI (reading, mobility, well-being) ranged from a low of − 0.2 to a high of 0.7 logits in those with RP and from 0.5 to 1.2 logits in those with glaucoma. Qualitative interviews identified six VR-QOL themes relevant across participants with both RP and glaucoma, including activity limitations, driving, emotional well-being, reading, mobility, and social function. VR-QOL concerns were largely consistent among those with severe PFL due to RP and glaucoma. These overarching themes contained content relevant to specific challenges related to severe PFL. Conclusions: There are commonly occurring VR-QOL concerns among individuals with severe PFL due to RP and glaucoma. The outlined themes will serve as the basis for development of the Low Vision Severely Constricted Peripheral Eyesight (LV-SCOPE) Questionnaire.
AB - Background: Existing patient-reported outcome (PRO) measures may not be relevant to the full range of functional and vision-related quality of life (VR-QOL) concerns of individuals with vision impairment due to severe peripheral field loss (PFL). Measurement of VR-QOL in severe PFL is important in order to determine the effectiveness of vision rehabilitation interventions for this population. The purpose of this study was to characterize the impact of severe PFL due to retinitis pigmentosa (RP) and glaucoma on VR-QOL as the initial phase in the development of a novel PRO measure. Methods: Individuals with severe PFL due to RP or glaucoma were recruited from the Kellogg Eye Center and the Association for the Blind and Visually Impaired. Participants completed semi-structured qualitative interviews, the Impact of Vision Impairment (IVI) questionnaire and the RAND 36-Item Health Survey. Interviews were analyzed by two coders using thematic analysis. A matrix analysis was conducted to compare VR-QOL by cause of severe PFL. Sample size was determined by thematic saturation. Results: The study included 37 participants (19 RP, 18 glaucoma). Median best-corrected visual acuity for those with RP and glaucoma was 20/40 and 20/27.5, while Pelli-Robson contrast sensitivity was 1.2 log contrast sensitivity (logCS) and 1.1 logCS, respectively. Median domain scores on the IVI (reading, mobility, well-being) ranged from a low of − 0.2 to a high of 0.7 logits in those with RP and from 0.5 to 1.2 logits in those with glaucoma. Qualitative interviews identified six VR-QOL themes relevant across participants with both RP and glaucoma, including activity limitations, driving, emotional well-being, reading, mobility, and social function. VR-QOL concerns were largely consistent among those with severe PFL due to RP and glaucoma. These overarching themes contained content relevant to specific challenges related to severe PFL. Conclusions: There are commonly occurring VR-QOL concerns among individuals with severe PFL due to RP and glaucoma. The outlined themes will serve as the basis for development of the Low Vision Severely Constricted Peripheral Eyesight (LV-SCOPE) Questionnaire.
KW - Glaucoma
KW - Interview
KW - Low vision
KW - Patient-reported outcome
KW - Peripheral field loss
KW - Peripheral vision
KW - Qualitative research
KW - Retinitis pigmentosa
KW - Vision rehabilitation
KW - Vision-related quality of life
UR - http://www.scopus.com/inward/record.url?scp=85099381704&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099381704&partnerID=8YFLogxK
U2 - 10.1186/s41687-020-00281-y
DO - 10.1186/s41687-020-00281-y
M3 - Article
C2 - 33439361
AN - SCOPUS:85099381704
SN - 2509-8020
VL - 5
JO - Journal of Patient-Reported Outcomes
JF - Journal of Patient-Reported Outcomes
IS - 1
M1 - 7
ER -